Lv11
70 积分 2023-12-06 加入
Phase I results for AMG 133
2小时前
已完结
A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity
8天前
已完结
Population Pharmacokinetics of Liraglutide, a Once‐Daily Human Glucagon‐Like Peptide‐1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice‐Daily Exenatide
20天前
已完结
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
20天前
已完结
Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies
23天前
已完结
Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment
1个月前
已完结
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
1个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
1个月前
已完结
Confidence interval criteria for assessment of dose proportionality
1个月前
已完结
Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide
2个月前
已完结
皖公网安备34019202002308
